By Dr Olivier Kadoch, obstetrician-gynaecologist · Updated 25/10/2026
Treatment of a gynaecological cancer in Paris (gynaecological oncology: cervix, endometrium, ovary) is based on a complete staging work-up and a joint decision at a multidisciplinary team meeting (in France, "RCP"). Surgery is performed at Clinique Ambroise Paré (Neuilly-sur-Seine). Surgery is part of a personalised care plan drawn up with the oncologist, the radiotherapist and the pathologist.
| Cancer | Warning sign | Tests | Role of surgery |
|---|---|---|---|
| Cervix | Bleeding after sex, abnormal smear or HPV test | Colposcopy, biopsies, MRI | Cone biopsy (conisation) for precancerous lesions; surgery for early stages |
| Endometrium | Bleeding after the menopause | Ultrasound, biopsy, MRI, molecular profiling | Hysterectomy, removal of the ovaries and fallopian tubes, sentinel lymph node |
| Ovary | Persistent bloating, swelling of the abdomen, a mass | Ultrasound, MRI, CT scan, tumour markers | Complete surgery in a specialist centre |
A meeting where surgeons, oncologists, radiotherapists, radiologists and pathologists decide together on the right treatment for each patient.
No, but it should always be investigated promptly with an ultrasound and, if needed, an endometrial biopsy.
For some early-stage cancers, fertility-sparing treatment is possible. This is discussed at a multidisciplinary tumour board (RCP) before any treatment, together with an oncofertility consultation.
It prevents the vast majority of infections with the HPV types that cause cervical cancer. Screening is still needed for vaccinated women.
It depends on the treatment decided at the RCP. As a rough guide, for a laparoscopic hysterectomy the stay is usually 2 to 4 days with about a month off work; for open surgery (laparotomy), 3 to 6 days and 4 to 8 weeks. Surgery is performed under general anaesthetic; you are given a written estimate beforehand and instructions are adapted to each patient.
Haute Autorité de santé (French National Authority for Health). Évaluation de la recherche des papillomavirus humains (HPV) en dépistage primaire des lésions précancéreuses et cancéreuses du col de l'utérus. Synthèse et recommandations. HAS, 2019. has-sante.fr
Haute Autorité de santé (French National Authority for Health). Papillomavirus (HPV) : le rattrapage vaccinal recommandé chez les femmes et les hommes jusqu'à 26 ans révolus. HAS, 2025. has-sante.fr
Concin N, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol, 2025. doi:10.1016/S1470-2045(25)00167-6 — PMID 40744042